US › Healthcare

Seres Therapeutics Inc (MCRB)

US · Healthcare · Biotechnology

$2.46-2.77%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$736,000

Net profit

$4.6M

EPS

$-1.50

EPS estimate

$-2.07

Net margin

622.4%

EPS came in at -1.50 against a street estimate of -2.07 — a beat of 27.5%.

Key statistics

Market cap

$25.4M

Forward P/E

10.3

P/B

1.17

Book value

$3.51

EPS (TTM)

$-2.42

52-week high

$29.98

52-week low

$2.38

50-day MA

$4.29

200-day MA

$7.96

Beta

0.31

Analyst view

Analysts rate Seres Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $17.00.

Shareholding

Insiders

11.49%

Institutions

22.93%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	11.51%
Vanguard Capital Management, LLC	2.86%
Marshall Wace Asset Management Ltd	1.71%
Vontobel Holding Ltd.	1.22%
BlackRock Inc	1.11%
Geode Capital Management, LLC	0.80%
Susquehanna International Group, LLP	0.58%
Vanguard Fiduciary Trust Co	0.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Seres Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.